USB:NYSEU.S. Bancorp Analysis
Data as of 2026-08-01 - not real-time
$63.01
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
U.S. Bancorp’s stock is trading just above its 20‑day simple moving average and comfortably above the 50‑day and 200‑day averages, confirming a sustained bullish bias. The price sits near a well‑defined support zone while still below the recent high‑water resistance, offering a modest upside cushion. Technical momentum is mixed – the RSI hovers in neutral territory and the MACD histogram has turned negative, suggesting short‑term caution despite the broader uptrend.
Fundamentally, the bank delivered a double‑digit revenue growth rate and strong profitability margins, with operating margins near 40% and net margins approaching 30%. Return on equity sits in the low‑teens and the dividend yield tops 3%, supported by a payout ratio well under 50%, indicating a sustainable income stream. Valuation metrics are attractive: the price‑to‑earnings multiple is well below the sector average and the price‑to‑book ratio is modest, positioning the stock on the undervalued side of the spectrum.
Recent material news reinforces the positive outlook. The company posted a 22% year‑over‑year earnings surge, lifted its full‑year revenue guidance, passed the Fed’s stress test, and announced an incremental dividend increase. Analyst sentiment has shifted to “Buy,” and the broader market sentiment is in “Extreme Greed,” further underpinning short‑term demand.
Fundamentally, the bank delivered a double‑digit revenue growth rate and strong profitability margins, with operating margins near 40% and net margins approaching 30%. Return on equity sits in the low‑teens and the dividend yield tops 3%, supported by a payout ratio well under 50%, indicating a sustainable income stream. Valuation metrics are attractive: the price‑to‑earnings multiple is well below the sector average and the price‑to‑book ratio is modest, positioning the stock on the undervalued side of the spectrum.
Recent material news reinforces the positive outlook. The company posted a 22% year‑over‑year earnings surge, lifted its full‑year revenue guidance, passed the Fed’s stress test, and announced an incremental dividend increase. Analyst sentiment has shifted to “Buy,” and the broader market sentiment is in “Extreme Greed,” further underpinning short‑term demand.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Price near support with mixed MACD signal
- Recent earnings beat and dividend increase
- Stable volume and low beta limiting downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Upgraded revenue outlook and strong loan growth
- Attractive valuation relative to peers
- Sustainable dividend yield above 3%
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust capital position and stress‑test pass
- Consistent profitability and solid ROE
- Low beta and defensive balance‑sheet profile
Key Metrics & Analysis
Financial Health
Revenue Growth10.40%
Profit Margin29.90%
P/E Ratio12.6
ROE12.62%
ROA1.16%
P/B Ratio1.6
Industry P/E18.0
Technical Analysis
TrendBullish
RSI55.0
Support$60.60
Resistance$64.84
MA 20$63.05
MA 50$59.61
MA 200$54.67
MACDBearish
VolumeStable
Fear & Greed Index92.88
Valuation
Target Price$70.32
Upside/Downside11.60%
GradeUndervalued
TypeBlend
Dividend Yield3.30%
Risk Assessment
Beta0.73
Volatility21.63%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.